DexCom (NASDAQ:DXCM) PT Raised to $185.00

DexCom (NASDAQ:DXCM) had its price objective hoisted by Bank of America from $162.00 to $185.00 in a report published on Thursday, BenzingaRatingsTable reports. They currently have a buy rating on the medical device company’s stock.

DXCM has been the topic of several other reports. JPMorgan Chase & Co. boosted their price target on shares of DexCom from $170.00 to $190.00 and gave the stock an overweight rating in a report on Thursday. TheStreet upgraded shares of DexCom from a d+ rating to a c rating in a report on Friday, June 28th. Northland Securities restated a hold rating and set a $125.00 price target on shares of DexCom in a report on Thursday, June 6th. BMO Capital Markets boosted their price target on shares of DexCom from $167.00 to $172.00 and gave the stock an outperform rating in a report on Thursday, May 2nd. Finally, Canaccord Genuity boosted their price target on shares of DexCom from $160.00 to $185.00 and gave the stock a buy rating in a report on Thursday. Five analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company’s stock. The stock has a consensus rating of Buy and an average price target of $163.71.

DexCom stock traded down $3.12 during midday trading on Thursday, hitting $141.09. 12,395 shares of the stock were exchanged, compared to its average volume of 853,906. DexCom has a 52-week low of $105.05 and a 52-week high of $161.30. The company has a market capitalization of $13.15 billion, a PE ratio of 468.67 and a beta of 0.80. The stock’s 50-day simple moving average is $149.93. The company has a quick ratio of 6.75, a current ratio of 6.05 and a debt-to-equity ratio of 1.56.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Wednesday, July 31st. The medical device company reported $0.08 earnings per share for the quarter, topping the consensus estimate of $0.01 by $0.07. DexCom had a negative net margin of 13.96% and a positive return on equity of 10.41%. The business had revenue of $336.40 million for the quarter, compared to analysts’ expectations of $304.40 million. During the same period in the previous year, the company earned ($0.10) earnings per share. The firm’s revenue for the quarter was up 38.7% compared to the same quarter last year. As a group, analysts predict that DexCom will post 0.94 EPS for the current year.

In other news, CEO Kevin R. Sayer sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $115.73, for a total value of $694,380.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Patrick Michael Murphy sold 400 shares of the business’s stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $116.92, for a total transaction of $46,768.00. The disclosure for this sale can be found here. In the last ninety days, insiders sold 63,065 shares of company stock worth $8,207,313. Insiders own 0.88% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the company. Blair William & Co. IL raised its position in shares of DexCom by 4.6% in the first quarter. Blair William & Co. IL now owns 1,010,355 shares of the medical device company’s stock valued at $120,333,000 after purchasing an additional 44,803 shares during the period. Virginia Retirement Systems ET AL raised its position in shares of DexCom by 230.6% in the first quarter. Virginia Retirement Systems ET AL now owns 16,200 shares of the medical device company’s stock valued at $1,929,000 after purchasing an additional 11,300 shares during the period. Robeco Institutional Asset Management B.V. raised its position in shares of DexCom by 32.0% in the first quarter. Robeco Institutional Asset Management B.V. now owns 162,127 shares of the medical device company’s stock valued at $19,307,000 after purchasing an additional 39,300 shares during the period. OLD National Bancorp IN raised its position in shares of DexCom by 1.1% in the second quarter. OLD National Bancorp IN now owns 9,838 shares of the medical device company’s stock valued at $1,474,000 after purchasing an additional 108 shares during the period. Finally, Allstate Corp bought a new stake in shares of DexCom in the first quarter valued at approximately $247,000. 96.21% of the stock is currently owned by institutional investors.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Further Reading: Put Option Volume

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.